PetVivo (PETV) Q1 2027 earnings summary

Executive summary

• Achieved 13% year-over-year revenue growth to $338,000 and 33% sequential growth, driven by focus on proprietary SPRYNG product and expanded sales force.

• Entered agreement to acquire PiezoBioMembrane (PBM), enhancing R&D and IP portfolio for regenerative biomaterials targeting both animal and human health.

• Advanced commercialization of AI-powered PetVivo.ai platform, targeting veterinary practice efficiency and customer acquisition.

• Net loss for the quarter was $1,613,888, a reduction from $2,311,037 in the prior year, primarily due to lower general and administrative and R&D expenses.

• The company operates in one segment, focusing on animal health products, with SPRYNG as its lead product for treating osteoarthritis in dogs and horses.

Financial highlights

• Revenue increased 13% year-over-year and 33% sequentially, totaling $338,000 for the quarter.

• Gross profit rose to $223,317 (66% margin), up from $186,726 year-over-year; margins expected to rise as sales shift fully to SPRYNG.

• Operating expenses decreased to $1,832,166 from $2,031,043 year-over-year, mainly due to reduced G&A and R&D costs.

• Operating loss improved 13% to $1.6 million; net loss was $1.7 million ($0.05/share), a 30% improvement from prior year.

• Net cash used in operations dropped 40% to $965,779; quarter-end cash was $123,000, with $1.35 million in equity subscription pending.

Outlook and guidance

• Anticipates continued sales momentum and market penetration for fiscal 2027 and beyond, supported by new product launches and international expansion.

• Expects gross margins to return to 80-90% range as sales transition fully to proprietary products.

• Management plans to improve operating results, reduce costs, increase revenues, and seek additional capital through debt and equity financing.

• The company is negotiating for up to $10 million in new investment and expects to continue raising capital to fund operations and expansion.

• There is substantial doubt about the company's ability to continue as a going concern within one year without additional financing.